Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine

Rheumatology

Volumn 38, Issue 7, 1999, Pages 640-644

  Naughton, M A ^a,d   Battaglia, E ^b   O'Brien, S ^c   Walport, M J ^a   Botto, M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Institute of Microbiology   (Italy)

^c CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^d ICSM   (United Kingdom)

Author keywords

Azathioprine; Genetics; Systemic lupus erythematosus; Thiopurine methyltransferase

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; THIOPURINE METHYLTRANSFERASE;

ARTICLE; BONE MARROW SUPPRESSION; DNA POLYMORPHISM; DRUG TOLERABILITY; ENTERITIS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

AZATHIOPRINE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHYLTRANSFERASES; NEUTROPENIA; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS;

EID: 0032732591     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.7.640     Document Type: Article

References (15)

1. Azathioprine. In: Dollery CT, ed. Therapeutic drugs, Vol. 1. London: Churchill Livingstone, 1991:A181-5.
2. Remy CN. Metabolism of thiopyrimidines and thiopurines: S-methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissue. J Biol Chem 1963;238:1078-84.
3. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651-62.
4. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte cor-relation and presence of isozymes. Pharmacogenetics 1992;2:148-59.
5. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
6. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
7. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995;92:949-53.
8. Tai HL, Krynetski EY, Yates CR et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996;58:694-702.
9. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
10. Otterness D, Szumlanski C, Lennard L et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73.
11. Tan EM, Cohen AS, Fries JS et al. 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
12. Klemetsdal B, Wist E, Aarbakke J. Gender difference in red blood cell thiopurine methyltransferase activity. Scand J Clin Lab Invest 1993;53:747-9.
13. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994;55:15-20.
14. McLeod HL, Krynetski EY, Wilimas JA, Evans WE. Higher activity of polymorphic thiopurine S-methyl-transferase in erythrocytes from neonates compared to adults. Pharmacogenetics 1995;5:281-6.
15. Pazmino PA, Sladek SL, Weinshilboum RM. Thiol S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors. Clin Pharmacol Ther 1980;28:356-67.